ArticleCell stem cell2023
SON is an essential m
Open access · greenAbstract read
In one paragraph
Article in Cell stem cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- A single-cell lens into the co-evolution of genotypes and phenotypes in cancer.Nature reviews. Cancer · 2026Review
- Targeting Osteoporosis-Osteoarthritis Comorbidity: Multi-Omics Identification of SON and Exploration of Therapeutic Agents.International journal of molecular sciences · 2026Article
- Interleukin-12 Supports Self-renewal Division of Mouse Hematopoietic Stem Cells in Polyvinyl Alcohol-Based Culture.Stem cell reviews and reports · 2026Article
- METTL3-mCellular & molecular biology letters · 2026Article
- NNature reviews. Cancer · 2026Review
- Nat10-mediated ac4C epitranscriptomics orchestrates hematopoietic stem/progenitor cell fate determination via translation control.Science advances · 2026Article
- Article
- Review
- The mMolecular biomedicine · 2025Review
- BCLAF1 restrains stress responses in hematopoietic stem cells to support expansion and repopulation.Blood advances · 2025Article
- Biomolecular condensates in immune cell fate.Nature reviews. Immunology · 2025Review
- Reprogramming of RNA m6A Modification Is Required for Acute Myeloid Leukemia Development.Genomics, proteomics & bioinformatics · 2025Article
- Natural medicines for treating liver fibrosis by modulating post-translational modifications.Frontiers in pharmacology · 2025Review
- mBiomaterials translational · 2025Review
- Epigenetic modifications in hematopoietic ecosystem: a key tuner from homeostasis to acute myeloid leukemia.Blood science (Baltimore, Md.) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Hanzhi LuoMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mariela Cortés-LópezNew York Genome Center, New York, NY, USA; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Institute of Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.
Cyrus L TamComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Tri-Institutional Training Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, NY, USA.
Michael XiaoMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Isaac WakiroMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Karen L ChuMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pharmacology, Weill Cornell School of Medical Sciences, New York, NY, USA.
Aspen PiersonMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mandy ChanMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kathryn ChangMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Xuejing YangMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniel FeckoMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Grace HanMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eun-Young Erin AhnDepartment of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Quaid D MorrisComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Tri-Institutional Training Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, NY, USA.
Dan A LandauNew York Genome Center, New York, NY, USA; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Institute of Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.
Michael G KharasMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: kharasm@mskcc.org.
Memorial Sloan Kettering Cancer Center · USCornell University · USUniversity of Alabama at Birmingham · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MThe Memorial Sloan Kettering Cancer Center SPORE in LeukemiaP50CA254838 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Eytan Stein · 2021 to 2026
$16.8MMechanisms of epitranscriptomic regulation in cancerR01CA186702 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SAMIE R JAFFREY, Michael Kharas · 2014 to 2026
$8.0MUncovering the role for MSI2 network in hematopoietic stem cellsR01DK101989 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Kharas, Vijay Ganesh Sankaran · 2014 to 2026
$6.2MCharacterizing the MSI2 network in leukemiaR01CA193842 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KHARAS, MICHAEL · 2015 to 2025
$4.1MIdentification of therapeutic targets for leukemia stem cells in AML-iPSC modelsR01CA225231 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KHARAS, MICHAEL, PAPAPETROU, EIRINI · 2018 to 2022
$3.2MInterrogation of the oxidative-stress-induced leukemia program in vivo usingmetabolic imagingR01CA283578 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kayvan R Keshari, Michael Kharas · 2023 to 2026
$3.0MMolecular and genetic analysis of novel Slicer-dependent miRNA pathways in bloodR01HL135564 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI KHARAS, MICHAEL, LAI, ERIC C · 2017 to 2020
$2.9MUnderstanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in LymphomaR01CA274249 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Kharas · 2023 to 2026
$2.8MCharting the differentiation topology of SF3B1 mutated clonal hematopoiesis (CH) and myelodysplastic syndromes (MDS) via a multi-omics single-cell toolkitR01HL157387 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LANDAU, DAN · 2022 to 2025
$2.7MPost-transcriptional Regulatory NetworksR01HG013328 · NHGRI · SLOAN-KETTERING INST CAN RESEARCH · PI Quaid Morris · 2023 to 2026
$2.6MGenetic and molecular basis of hematopoietic abnormalities in ZTTK syndromeR01HL168659 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Erin Eun-Young Ahn · 2023 to 2026
$2.1MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA254838NCI NIH HHS R01 CA186702NCI NIH HHS R01 CA193842NCI NIH HHS R01 CA225231NCI NIH HHS R01 CA236911NCI NIH HHS R01 CA274249NCI NIH HHS R01 CA283578NHGRI NIH HHS R01 HG013328NHLBI NIH HHS R01 HL135564NHLBI NIH HHS R01 HL157387NHLBI NIH HHS R01 HL168659NIDDK NIH HHS K99 DK128602NIDDK NIH HHS R01 DK101989
Abstract
Stem cells regulate their self-renewal and differentiation fate outcomes through both symmetric and asymmetric divisions. m
Indexed as
DNA-Binding ProteinsHematopoietic Stem CellsInflammationRNA MethylationAdenosineAnimalsCell DifferentiationHumansMethylationMethyltransferasesMiceMinor Histocompatibility AntigensNuclear ProteinsRNA, MessengerAdenosineDNA-Binding ProteinsMethyltransferasesMETTL3 protein, humanMinor Histocompatibility AntigensN-methyladenosineNuclear ProteinsRNA, MessengerSON protein, humanSon protein, mousecell fatedifferentiationhematopoietic stem cellsinflammationnuclear specklesRNA binding proteinsRNA methylationRNA modificationsSONstem cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.